





Regulatory requirements

New developments and challenges on vaccine regulation



Program of the day



S₁

- Title: Intro to vaccine procurement and regulatory issues
- Objective: understanding regulatory challenges and constrains

S2

- Title: Focused country exchange on vaccine regulatory issues
- Objective: Mapping major country regulatory requirements

S3

- Title: Introduction to vaccine registration processes and issues
- Objective: Knowing regulatory pathways and Good Regulatory Practices

S4

- Title: Focused country exchange on vaccine registration processes and issues
- Objective: Develop a plan to address regulatory challenges





Outline




- Global NRA status
- Global context: SDG and WHA Resolution for Regulatory System Strengthening
- WHO Regulatory System Capacity Building Model
- WHO Global Benchmarking Tool
- Measuring performance of regulatory systems
- Global overview





Overall regulatory systems' maturity level of WHO Member States





(Updated 8 Feb 2019) WHO MVP/RSS/CRS







SUSTAINABLE GEALS DEVELOPMENT GEALS



SDG 3 - Target 3.8

13 CLIMATE ACTION



Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all.





WHA Resolution 67.20



What WHO should do

To continue to support Member States upon their request in the area of regulatory system strengthening, including, as appropriate, by continuing to:

 $\mathsf{E_{v_{al_{u_{at_e}}}}}$

Evaluate national regulatory systems

Tools

Apply WHO evaluation tools

Performance

Generate and analyze evidence of regulatory system performance

IDPs

Facilitate the formulation and implementation of institutional development plans

Technical support

Provide technical support to national regulatory authorities and governments







WHO capacity building model








WHO NRA 5 step capacity building










Access to Safe, Effective, Quality and Affordable Medical Products




WHO Global Benchmarking Tool



Structure/Hierarchy

National Regulatory System (NRS) and Functions (NRF)







WHO Global Benchmarking Tool



Structure/Hierarchy

Indicators Categorization (cross cutting subjects)



Monitoring progress and assessing impact





Essential medicines and health products

WHO Global Benchmarking Tool (GBT) for

Medicines and health products

About us

Access and innovation

evaluation of national regulatory systems

Regulatory systems play a key role in assuring the quality, safety, and efficacy of medical products. Effective regulatory systems are an essential component of health systems and contribute to desired public health outcomes and innovation.



Related links

National Regulatory Systems

ting

sheet

nts (LI)

in (RI) fact

Regulation

Publication

News

Contacts

WHO Global Benchmarking Tool (GBT) Rev VI

https://www.who.int/medicines/regulation/benchmarking_tool/en/

The development of the current GBT Revision VI takes into consideration input received from two international consultations with Member States in 2015, a public consultation in early 2018 and a series of meetings involving experts from regulatory authorities from different parts of the world.

The GBT Revision VI replaces all tools previously used by WHO, representing the first truly 'global' tool for benchmarking regulatory systems. The GBT is designed to evaluate the overarching regulatory framework and the component regulatory functions (e.g. clinical trial oversight) through a series of sub-indicators that may also be grouped and examined according to nine cross-cutting categories or themes, for example, quality and risk management system. Fact sheets have been developed for

pdf, 1.03Mb

Laboratory Testing (LT) fact
sheet
pdf, 1.02Mb

Clinical Trials Oversight (CT)
fact sheet

NRA Lot Release (LR)

pdf, 1.03Mb

factsheet

nelf 011lds

sheet

WHO GBT Performance Maturity Levels

1

No formal approach

Some elements of regulatory system exist

2

Reactive approach

Evolving national regulatory system that partially performs essential regulatory functions

Can ensure the quality of products if rely on ML 3/ ML 4 regulatory systems

100 Countries 44 Countries 3

Stable formal system approach

Stable, wellfunctioning and integrated regulatory system

Target of WHA Resolution 67.20

4

Continual improvement emphasized

Regulatory system operating at advanced level of performance and continuous improvement

Advanced and well resourced regulatory systems

50 Countries

24/04/2019


ISO 9004

GBT

13

China: The Success Story







Fact and figures GLOBAL OVERVIEW



Countries/areas targeted for WHO Regulatory System **Strengthening Program and benchmarked against GBT indicators** between 2016- Feb 2019




Formal Benchmarking

- India
- Papua new guinea
- Timor-Leste
- Tanzania
- Burundi
- Ethiopia
- Mozambique
- Kenya
- Diibouti
- Eritrea
- Sudan
- South Sudan
- Somalia
- Uganda
- Serbia
- Cambodia
- Lao PDR
- Thailand
- Indonesia
- Kazakhstan
- Vietnam

(Updated 15 Feb 2019)

Rwanda



Guinea Bissau

Liberia

Niger

Cape Verde

Nigeria

Turkey

China

Nepal

Sri Lanka

Cote d'ivoire

Bhutan

Senegal Togo

Mali

Self Benchmarking


- Afghanistan
- Pakistan
- Malaysia
- Japan
- Iraq
- Jordan
- Lebanon
- Mongolia
- Kyrgyzstan
- Korea
- Bangladesh
- Iran
- Syria
- Egypt
- Saudi Arabia
- Gambia
- Benin
- **Burkina Faso**
- Guinea
- Sierra Leone
- Montenegro
 - Bosnia and Herzegovina
 - Macedonia
 - Albania
- Kosovo area*

STRENGTHENING NATIONAL REGULATORY AUTHORITY (NRA) TRAINING CONDUCTED 1996-2018



8800 PARTICIPANTS FROM NRAs, NCLs*, EPIs** AND/OR VM***

8800 head counts have been trained by WHO between 1996 till Dec 2018



Source: WHO/EMP


^{*} National Control Laboratory

^{**} Expanded Programme on Immunization

^{***} Vaccine Manufacture

Number of trainees per country 1996-2018









CRS Group





Sillo, Hiiti Baran Silloh@who.int



MELOUNOU, Yvonne melounouy@who.int



KHADEM BROOJERDI, Alireza khadembroojerdia@who.int



REFAAT, Mohamed refaatm@who.int



OSTAD ALI DEHAGHI, Razieh ostadalidehaghir@who.int



SHERIF, Mohamed sherifm@who.int



BROWN, Laura Kay brownl@who.int



MAGDY, Alaa magdya@who.int



YAP, Maria Bernadette yapm@who.int



Important Links











Go to SharePoint site













Dr Alireza Khadem

Email: khadembroojerdia@who.int

Regulatory Systems Strengthening (RSS)

Regulation of Medicines and Other Health Technologies (RHT)

World Health Organization (Geneva, Switzerland)



